Omeprazole
From £12.99
The Molecular Mechanism of Proton Pump Inhibition
Understanding Gastric Acid Production
The stomach produces acid through specialised cells called gastric parietal cells, located in the stomach lining. These cells contain an enzyme system known as hydrogen-potassium adenosine triphosphatase (H+/K+-ATPase), commonly referred to as the proton pump. This enzyme is responsible for the final step in acid production, actively transporting hydrogen ions into the stomach cavity where they combine with chloride ions to form hydrochloric acid.
Omeprazole's Mechanism of Action
Omeprazole belongs to a class of medications called proton pump inhibitors (PPIs). Unlike antacids that neutralise existing acid or H2 receptor antagonists that block histamine signals, omeprazole works by irreversibly binding to the proton pump enzyme itself. Once omeprazole is absorbed and reaches the acidic environment of the parietal cells, it becomes activated and forms covalent bonds with specific cysteine residues on the H+/K+-ATPase enzyme, effectively blocking its function.
Clinical Efficacy and Duration
Research published in the British National Formulary (BNF) demonstrates that omeprazole can reduce gastric acid secretion by 70-80% within the first dose. The irreversible nature of this binding means that acid production remains suppressed until new proton pump enzymes are synthesised by the cells, typically taking 24-72 hours. This explains why omeprazole provides sustained relief and why it's most effective when taken before the first meal of the day.
Bioavailability and Metabolism
Omeprazole is formulated as enteric-coated capsules or tablets to protect the active ingredient from stomach acid degradation. The medication has approximately 35-60% bioavailability, which increases with repeated dosing as acid levels decrease. Omeprazole is metabolised primarily by the liver enzyme CYP2C19, with genetic variations in this enzyme affecting individual response rates.
Treatment Options Available
EverydayMeds offers several PPI options including Omeprazole 20mg Capsules as the primary treatment, alongside Losec MUPS 20mg (branded omeprazole), Lansoprazole 15mg Capsules, Pantoprazole 20mg Tablets, and Esomeprazole Tablets. For patients who may not respond well to PPIs, Famotidine Tablets provide an H2 receptor antagonist alternative. The choice between these options often depends on individual patient factors, symptom severity, and previous treatment response.
Long-term Safety Considerations
Clinical studies referenced in the BNF indicate that omeprazole is generally well-tolerated for both short-term and long-term use. However, prolonged acid suppression may affect nutrient absorption, particularly magnesium, vitamin B12, and iron. Regular monitoring is recommended for patients on long-term therapy, especially those over 65 years of age or with additional risk factors.
